By Fineline Cube 
Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September 30, 2025. For the first nine months of 2025 the company posted revenue of $32.869 B, a year‑over‑year (YoY) increase of 6.1 %. In the third quarter alone, revenue reached $11.369 B, up 6.9 % YoY. Operating margin stood at 18.1 % of sales, while the adjusted operating margin rose 23.0 %, reflecting a 40‑basis‑point lift.
Segment Performance – Q3 2025
| Segment | Revenue | YoY Change | Key Drivers |
|---|---|---|---|
| Nutrition | $2.153 B | +4.2 % | Growth of Ensure® and Glucerna brands |
| Diagnostics | $2.253 B | –6.6 % (incl. COVID‑19) | 0.4 % organic growth; China procurement headwinds |
| Established Pharmaceuticals | $1.511 B | +7.5 % | 10.3 % reported, 11.1 % organic growth in Emerging Markets |
| Medical Devices | $5.448 B | +14.8 % | Double‑digit gains in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure, Structural Heart |
Diabetes Care Highlights
Continuous glucose monitors (CGMs) sales totaled $2.0 B, a 20.5 % increase YoY.
Guidance & Outlook
Abbott reaffirms its full‑year 2025 organic sales growth guidance of 7.5 % to 8.0 % (excluding COVID‑19 testing sales) or 6.0 % to 7.0 % (including COVID‑19 sales). The company remains confident that its diversified portfolio and strong pipeline will sustain growth momentum into 2026.
Investor Takeaways
- Revenue growth driven by Nutrition and Medical Devices segments.
- Operating margin improvement reflects cost discipline and high‑margin product mix.
- Diagnostics growth is muted, primarily due to external market forces rather than product performance.-Fineline Info & Tech